Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00822107 · ClinicalTrials.gov registry record · NA
A Translational Approach to Gitelman Syndrome
A NA study, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- NA
- Development phase
- 8
- Enrollment target
NCT00822107 is a NA study that has completed, run by Oregon Health and Science University. The registered enrollment target is 8 participants.
The verdict
NCT00822107, a NA study, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
Study Summary
This study will test the response to a single dose of thiazide diuretic as a diagnostic test for Gitelman syndrome. Individuals with hypokalemic alkalosis will be enrolled. After a baseline study, they will have the response to 50 mg hydrochlorothiazide on fractional chloride excretion examined.
Interventions
- DRUG Hydrochlorothiazide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2009-01 |
| Est. Completion | 2013-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00822107
The ClinicalTrials.gov registry entry for NCT00822107 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Hydrochlorothiazide is the first listed.
NCT00822107 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00822107 about?
NCT00822107 is a clinical study titled "A Translational Approach to Gitelman Syndrome". This study will test the response to a single dose of thiazide diuretic as a diagnostic test for Gitelman syndrome. Individuals with hypokalemic alkalosis will be enrolled. After a baseline study, they will have the response to 50 mg hydrochlorothiazide on fractional chloride excretion examined.
What is the current status of trial NCT00822107?
This trial is currently completed. It is a NA study. The enrollment target is 8 participants. The study started on 2009-01. Estimated completion is 2013-09.
What interventions are being tested in trial NCT00822107?
The interventions under investigation include: Hydrochlorothiazide (DRUG).
Who is sponsoring clinical trial NCT00822107?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.